New Data at ASH 2022 Bolster Servier’s Leadership in Hematology Research
Discover our news
Servier Pharmaceuticals Partners with Artists for Humanity
Servier Summer Interns Share Their Experiences
Servier Affirms Commitment to Cancer by Announcing the Opening of a Global R&D Center and Expanded Offices in Boston’s Seaport
Servier Statement on U.S. Supreme Court Overturning Roe v. Wade
Reaching New Heights Through the Climb to Fight Cancer Expedition
Servier to Showcase Growing Oncology Portfolio at the ASCO and EHA 2022 Annual Meetings
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia
Overcoming the Medical Industry’s Supply Chain Challenges